sNFL applicability as additional monitoring tool in Natalizumab Extended Interval Dosing regimen for RRMS patients

被引：0
|
作者：
Valentino, P. [1 ,2 ]
Malucchi, S. [3 ]
Martire, S. [4 ]
Bava, C. I. [1 ]
Capobianco, M. A. [2 ,5 ]
Bertolotto, A. [1 ,6 ]
机构：
[1] Neurosci Inst Cavalieri Ottolenghi NICO, Orbassano, Italy
[2] Univ Hosp San Luigi Gonzaga, CRESM Biobank, Orbassano, Italy
[3] Univ Hosp San Luigi Gonzaga, Neurol, Orbassano, Italy
[4] Univ Turin, Neurosci, Turin, Italy
[5] S Croce Carle Hosp, Neurol, Cuneo, Italy
[6] Koelliker Hosp, Turin, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1244
引用
收藏
页码：1006 / 1007
页数：2
相关论文
共 50 条
  • [31] Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
    Ryerson, Lana Zhovtis
    Foley, John
    Chang, Ih
    Kister, Ilya
    Cutter, Gary
    Metzger, Ryan R.
    Goldberg, Judith D.
    Li, Xiaochun
    Riddle, Evan
    Smirnakis, Karen
    Kasliwal, Rachna
    Ren, Zheng
    Hotermans, Christophe
    Ho, Pei-Ran
    Campbell, Nolan
    NEUROLOGY, 2019, 93 (15) : E1452 - E1462
  • [32] Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial
    van Kempen, Zoe L. E.
    Hoogervorst, Erwin L. J.
    Wattjes, Mike P.
    Kalkers, Nynke F.
    Mostert, Jop P.
    Lissenberg-Witte, Birgit I.
    de Vries, Annick
    ten Brinke, Anja
    van Oosten, Bob W.
    Barkhof, Frederik
    Teunissen, Charlotte E.
    Uitdehaag, Bernard M. J.
    Rispens, Theo
    Killestein, Joep
    NEUROLOGY, 2020, 95 (06) : E745 - E754
  • [33] Natalizumab extended-interval dosing in a real-life setting
    Jeantin, Lina
    de la Motte, Marine Boudot
    Deschamps, Romain
    Gueguen, Antoine
    Gout, Olivier
    Lecler, Augustin
    Papeix, Caroline
    Bensa, Caroline
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 450
  • [34] Effectiveness and safety profile of the natalizumab extended interval dosing in a spanish cohort
    Costa-Frossard, L.
    Sainz De La Maza, S.
    Monreal, E.
    Gomez Lopez, A.
    Fernandez-Velasco, J. I.
    Walo Delgado, P.
    Espino, M.
    Villarrubia, N.
    Masjuan, J.
    Villar, L. M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 278 - 278
  • [35] Exploratory PML risk assessment on Extended Interval Natalizumab Dosing.
    Ryerson, Lana Zhovtis
    Foley, John
    Kister, Ilya
    Frohman, Teresa
    Pandey, Krupa
    Lu, Xiaochun
    Goldberg, Judith
    Zuniga-Estrada, Guadalupe
    Hoyt, Tammy
    Jacob, April
    Bacon, Tamar
    Major, Eugene
    Frohman, Elliot
    NEUROLOGY, 2017, 88
  • [36] Extended dosing interval reduces risk of natalizumab-related PML
    Reactions Weekly, 2019, 1772 (1) : 9 - 9
  • [37] Mri activity and extended interval of natalizumab dosing: a multicenter italian study
    Clerico, M.
    De Mercanti, S. F.
    Signori, A.
    Iudicello, M.
    Cordioli, C.
    Signoriello, E.
    Lus, G.
    Bonavita, S.
    Lavorgna, L.
    Maniscalco, G. T.
    Curti, E.
    Lorefice, L.
    Cocco, E.
    Nociti, V.
    Mirabella, M.
    Baroncini, D.
    Mataluni, G.
    Landi, D.
    Petruzzo, M.
    Lanzillo, R.
    Gandoglia, I.
    Laroni, A.
    Frangiamore, R.
    Sartori, A.
    Cavalla, P.
    Costantini, G.
    Sormani, M. P.
    Capra, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 538 - 538
  • [38] Real world effectiveness of Natalizumab extended interval dosing in a French cohort
    Pelle, J.
    Briant, A.
    Lebrun-Frenay, C.
    Cohen, M.
    Mondot, L.
    De Seze, J.
    Bigaut, K.
    Collongues, N.
    Kremer, L.
    Ricard, D.
    Bompaire, F.
    Sallansonnet-Froment, M.
    Ohlmann, C.
    Ciron, J.
    Biotti, D.
    Pignolet, B.
    Parienti, J.
    Defer, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 207 - 207
  • [39] Extended interval dosing of natalizumab shows comparable efficacy to standard interval dosing starting from the second year of treatment
    Ruggieri, S.
    Ianniello, A.
    De Giglio, L.
    Altieri, M.
    Centonze, D.
    Cortese, A.
    Fantozzi, R.
    Galgani, S.
    Gasperini, C.
    Landi, D.
    Marfia, G. A.
    Mirabella, M.
    Nistri, R.
    Nociti, V.
    Romano, S.
    Salvetti, M.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 1009 - 1010
  • [40] Natalizumab wearing-off symptoms Patients with MS on extended interval dosing may not "mind the gap"
    Mowry, Ellen M.
    Bourdette, Dennis
    NEUROLOGY, 2019, 93 (17) : 735 - 736
12345